JP2024509282A - ガラクトース欠損免疫グロブリンの二官能性分解剤 - Google Patents

ガラクトース欠損免疫グロブリンの二官能性分解剤 Download PDF

Info

Publication number
JP2024509282A
JP2024509282A JP2023555333A JP2023555333A JP2024509282A JP 2024509282 A JP2024509282 A JP 2024509282A JP 2023555333 A JP2023555333 A JP 2023555333A JP 2023555333 A JP2023555333 A JP 2023555333A JP 2024509282 A JP2024509282 A JP 2024509282A
Authority
JP
Japan
Prior art keywords
optionally substituted
group
groups
independently
moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023555333A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024509282A5 (cg-RX-API-DMAC10.html
Inventor
エム ドゥボウチック,ジーン
スピーゲル,デヴィッド
エム コールドウェル,リース
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biohaven Therapeutics Ltd
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Publication of JP2024509282A publication Critical patent/JP2024509282A/ja
Publication of JP2024509282A5 publication Critical patent/JP2024509282A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2023555333A 2021-03-10 2022-03-10 ガラクトース欠損免疫グロブリンの二官能性分解剤 Pending JP2024509282A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163159383P 2021-03-10 2021-03-10
US63/159,383 2021-03-10
PCT/US2022/019658 WO2022192478A1 (en) 2021-03-10 2022-03-10 Bifunctional degraders of galactose-deficient immunoglobulins

Publications (2)

Publication Number Publication Date
JP2024509282A true JP2024509282A (ja) 2024-02-29
JP2024509282A5 JP2024509282A5 (cg-RX-API-DMAC10.html) 2025-03-19

Family

ID=83227063

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023555333A Pending JP2024509282A (ja) 2021-03-10 2022-03-10 ガラクトース欠損免疫グロブリンの二官能性分解剤

Country Status (11)

Country Link
US (2) US20240309114A1 (cg-RX-API-DMAC10.html)
EP (1) EP4304579A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024509282A (cg-RX-API-DMAC10.html)
KR (1) KR20230154900A (cg-RX-API-DMAC10.html)
CN (1) CN116997337A (cg-RX-API-DMAC10.html)
AU (1) AU2022232620A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023017702A2 (cg-RX-API-DMAC10.html)
CA (1) CA3211335A1 (cg-RX-API-DMAC10.html)
IL (1) IL305665A (cg-RX-API-DMAC10.html)
MX (1) MX2023010424A (cg-RX-API-DMAC10.html)
WO (1) WO2022192478A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12023553152A1 (en) * 2021-05-17 2024-03-11 Biohaven Therapeutics Ltd Compositions including conjugated therapy enhancers
JP2024524614A (ja) 2021-07-14 2024-07-05 ライシア セラピューティクス, インコーポレイテッド Asgpr細胞表面受容体結合化合物及びコンジュゲート
CN121038815A (zh) * 2023-04-29 2025-11-28 拜奥海芬治疗学有限公司 半乳糖缺陷型免疫球蛋白的双功能降解剂
WO2026083257A1 (en) 2024-10-14 2026-04-23 Biohaven Therapeutics Ltd. Antigen-specific degraders of immunoglobulin a and their uses
WO2026120177A1 (en) 2024-12-06 2026-06-11 Ascendis Pharma A/S Novel long-acting degrader conjugates

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019199634A1 (en) * 2018-04-09 2019-10-17 Yale University Bifunctional small molecules to target the selective degradation of circulating proteins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8440191B2 (en) * 2005-11-18 2013-05-14 Tufts Medical Center Clearance of abnormal IGA1 in IGA1 deposition diseases
DK2991683T3 (da) * 2013-05-02 2019-11-04 Glykos Finland Oy Konjugater af et glykoprotein eller en glykan med en toksisk ladning
CA2946064C (en) * 2014-02-21 2023-09-26 Ecole Polytechnique Federale De Lausanne (Epfl) Glycotargeting therapeutics
RU2696490C2 (ru) * 2014-05-19 2019-08-02 Пфайзер Инк. Замещенные-6,8-диоксабицикло[3.2.1.]октан-2,3-диольные соединения в качестве агентов, нацеленных на ASGPR

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019199634A1 (en) * 2018-04-09 2019-10-17 Yale University Bifunctional small molecules to target the selective degradation of circulating proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ACS CENT SCI, vol. vol. 7(3), JPN6026021782, 4 March 2021 (2021-03-04), pages 499 - 506, ISSN: 0005874929 *
CLIN IMMUNOL, vol. 172, JPN6026021781, 18 July 2016 (2016-07-18), pages 72 - 77, ISSN: 0005874928 *

Also Published As

Publication number Publication date
US20260146106A1 (en) 2026-05-28
BR112023017702A2 (pt) 2023-12-12
CA3211335A1 (en) 2022-09-15
MX2023010424A (es) 2023-09-18
EP4304579A4 (en) 2026-06-10
US20240309114A1 (en) 2024-09-19
IL305665A (en) 2023-11-01
KR20230154900A (ko) 2023-11-09
WO2022192478A1 (en) 2022-09-15
CN116997337A (zh) 2023-11-03
AU2022232620A1 (en) 2023-09-21
EP4304579A1 (en) 2024-01-17

Similar Documents

Publication Publication Date Title
JP7861064B2 (ja) 抗体-薬物コンジュゲート用のグリコシド含有ペプチドリンカー
KR20230154900A (ko) 갈락토스-결핍 면역글로불린의 이중기능성 분해제
JP2024096335A (ja) 親水性抗体-薬物コンジュゲート
JP2022105640A (ja) 四級化チューブリシン化合物の複合体
KR20230133312A (ko) 캄프토테신 항체-약물 접합체 및 이의 사용 방법
JP2023116497A (ja) シクロデキストリンタンパク質薬物コンジュゲート
JP2021513844A (ja) グリピカン3抗体およびそのコンジュゲート
TWI838358B (zh) 疏水性奧瑞他汀(auristatin)f化合物及其結合物
KR20260053443A (ko) 항체-페이로드 컨쥬게이트 제조용 화합물, 이의 용도
TW202241522A (zh) 免疫刺激化合物及結合物
JP2025510623A (ja) Ptk7を発現する腫瘍を標的化するための抗体コンジュゲート
JP2024529466A (ja) 抗体薬物コンジュゲート及びその使用方法
TWI820038B (zh) 妥布賴森(tubulysins)及其中間產物之製備方法
JP2025510700A (ja) Trop-2を発現する腫瘍を標的化するための抗体コンジュゲート
EP4277662A1 (en) Dual-cleavage ester linkers for antibody-drug conjugates
TW202233560A (zh) 肽交聯劑及以該交聯劑交聯之交聯肽
JP2023551203A (ja) 抗体-薬物コンジュゲートのためのグリコシド二重切断リンカー
RU2859790C2 (ru) Сложноэфирные линкеры с двойным расщеплением для конъюгатов антитело-лекарственное средство
CN116847844A (zh) 喜树碱抗体-药物缀合物及其使用方法
WO2026026939A1 (zh) 抗cd74抗体、抗体-药物缀合物及其制备方法和用途
WO2024098023A2 (en) Interferon alpha polypeptides and conjugates
KR20250160368A (ko) 뮤신-1에 특이적인 항체 접합체 및 그의 사용 방법
CN118339165A (zh) 抗体-药物缀合物及其使用方法
HK40092909A (en) Peptide crosslinking agent and crosslinked peptide which is crosslinked using said crosslinking agent

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260602